RESEARCH ARTICLE

Rifampicin-Induced Hepatic Lipid Accumulation: Association with Up-Regulation of Peroxisome Proliferator-Activated Receptor γ in Mouse Liver

Jia-Hui Huang1*, Cheng Zhang2*, Da-Gang Zhang1, Lu Li1, Xi Chen1*, De-Xiang Xu2*

1 First Affiliated Hospital, Anhui Medical University, Hefei, China, 2 Department of Toxicology, Anhui Medical University, Hefei, China

☯ These authors contributed equally to this work.
* ayfychenxi@163.com (XC); xudex@126.com (DXX)

Abstract

Previous study found that rifampicin caused intrahepatic cholestasis. This study investigated the effects of rifampicin on hepatic lipid metabolism. Mice were orally administered with rifampicin (200 mg/kg) daily for different periods. Results showed that serum TG level was progressively reduced after a short elevation. By contrast, hepatic TG content was markedly increased in rifampicin-treated mice. An obvious hepatic lipid accumulation, as determined by Oil Red O staining, was observed in mice treated with rifampicin for more than one week. Moreover, mRNA levels of Fas, Acc and Scd-1, several key genes for fatty acid synthesis, were elevated in rifampicin-treated mice. In addition, the class B scavenger receptor CD36 was progressively up-regulated by rifampicin. Interestingly, hepatic SREBP-1c and LXR-α, two important transcription factors that regulate genes for hepatic fatty acid synthesis, were not activated by rifampicin. Instead, hepatic PXR was rapidly activated in rifampicin-treated mice. Hepatic PPARγ, a downstream target of PXR, was transcriptionally up-regulated. Taken together, the increased hepatic lipid synthesis and uptake of fatty acids from circulation into liver jointly contribute to rifampicin-induced hepatic lipid accumulation. The increased uptake of fatty acids from circulation into liver might be partially attributed to rifampicin-induced up-regulation of PPARγ and its target genes.

Introduction

Nonalcoholic fatty liver disease (NAFLD) has been considered the most common chronic liver disease in developed countries and has been gradually increasing in Chinese adults in recent decades [1,2]. The hallmark of NAFLD is excessive triglyceride (TG) accumulation in liver [3]. NAFLD represents a wide spectrum liver disease ranging from simple hepatic steatosis to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and even hepatocellular carcinoma [4]. Although obesity, type 2 diabetes, high-fat diets, insulin resistance and metabolic syndrome have been
recognized as common risk factors of NAFLD [5], drug-induced hepatic steatosis and steatohepatitis are considered a rare but very important forms of NAFLD [6].

Rifampicin, one of the most commonly used front-line drugs in antituberculosis therapy, has been well known to be hepatotoxic [7, 8]. Two in vitro studies showed that rifampicin caused a direct toxic injury to rat hepatocytes [9, 10]. Several in vivo studies found that rifampicin plus isoniazid induced hepatocyte apoptosis in rodent animals [11–13]. The mechanism through which rifampicin induces liver injury remains obscure. An earlier study demonstrates that oxidative stress in the mitochondria is involved in the pathogenesis of rifampicin plus isoniazid-induced apoptotic liver cell injury in mice [14]. According to a report from our laboratory, rifampicin causes intrahepatic cholestasis through altering integrity of hepatocyte ZO-1 and occluding [15].

The aim of the present study was to explore the effects of rifampicin on hepatic lipid metabolism in mice. We showed that rifampicin elevated hepatic TG content and caused hepatic lipid accumulation. We found that rifampicin up-regulated genes for synthesis and transport of hepatic fatty acids. Our results suggest that the increased hepatic lipid synthesis and uptake of fatty acids from circulation into liver partially contribute to rifampicin-induced hepatic lipid accumulation. The increased uptake of fatty acids from circulation into liver might be attributed to rifampicin-induced up-regulation of peroxisome proliferator-activated receptor γ (PPARγ) and its target genes.

Materials and Methods

Chemicals

Rifampicin was purchased from Sigma Chemicals Co. (St. Louis, MO, USA). Antibodies against SREBP-1c, LXR-α, PXR, PPARγ, and Lamin A/C were from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Chemiluminescence (ECL) detection kit was from Pierce Biotechnology (Rockford, IL, USA). TRI reagent was from Invitrogen (Carlsbad, CA, USA). RNase-free DNase was from Promega Corporation (Madison, WI, USA). Oil Red O was from Sigma Chemical Co. (St Louis, MO, USA). All the other reagents were from Sigma or as indicated in the specific methods.

Animals and treatment

Thirty-two male CD-1 mice were purchased from the Laboratory Animal Center of Anhui Medical University. The animals were maintained on a 12-h light/dark cycle in a controlled temperature (20–25°C) and humidity (50±5%) environment for a period of 1 week before use. All mice were fed with regular diet. To investigate the effect of rifampicin on hepatic lipid accumulation, mice were divided into four groups. All mice except controls were orally administered with rifampicin (200 mg/kg) daily for 3 days, 1 week or 4 weeks, respectively. All thirty-two male CD-1 mice survived to the end of the experiments. All mice were anesthetized with ether and then sacrificed with dislocation of cervical vertebrae 6 h after the last rifampicin treatment. Serum was collected for measurement of biochemical parameters. Liver was collected and frozen immediately in liquid nitrogen for hepatic TG measurement, real-time RT-PCR and Western Blot, fixed in neutral-buffered formalin for histological examination, or frozen fixed in OCT mounting media for Oil red O staining. This study was approved by the Association of Laboratory Animal Sciences and the Center for Laboratory Animal Sciences at Anhui Medical University (Permit Number: 15–0010). All procedures on animals followed the guidelines for humane treatment set by the Association of Laboratory Animal Sciences and the Center for Laboratory Animal Sciences at Anhui Medical University. In this study, all mice were monitored at least twice per day. In addition, the rules of humane endpoints were strictly...
performed to determine when mice should be euthanized. All efforts were taken to minimize suffering when mice met our euthanasia criteria.

Biochemical parameters and hepatic histology

Serum alanine transaminase (ALT), TG, total cholesterol (TC), high density lipoprotein cholesterol (Chol-HDL) and very low density lipoprotein TG (TG-VLDL) were measured by routine laboratory methods using an autoanalyzer (Roche, Modular DPP, NO. 1549–06). Liver specimen was fixed in 4% paraformaldehyde phosphate buffer. Liver sections were stained with hematoxylin and eosin and evaluated by the pathologists who were blind to sample assignment to experimental groups.

Hepatic TG measurement

For measurement of hepatic TG content, liver samples were homogenized in 2 ml of buffer that contains 18 mM Tris (pH 7.5), 300 mM mannitol, 50 mM EGTA, and 0.1 mM PMSF. For extraction of hepatic TG, 400 μl of tissue homogenate was mixed with 4 ml of chloroform/methanol (2:1) and incubated with shaking overnight at room temperature. Finally, 800 μl of H₂O was then added and vortexed, centrifuged at 3000 g for 5 min, and the lower lipid phase was collected and dried. The lipid pellets were then dissolved in a 100 μl mixture of tert-butyl alcohol/ Triton X-114/methanol (4.6:2:1) [16]. TG was determined by a commercially available kit. Hepatic TG contents were expressed as μmol/g liver.

Oil Red O staining

To determine hepatic lipid accumulation, frozen sections of liver (10 μm) were stained with Oil Red O for 10 min, washed, and counterstained with hematoxylin for 45s. Representative photomicrographs were captured at 100× magnification using a system incorporated in the microscope.

Isolation of total RNA and real-time RT-PCR

Total RNA was extracted using TRI reagent. RNase-free DNase-treated total RNA (1.0 μg) was reverse-transcribed with AMV (Promega Corp., Madison, WI, USA). Real-time RT-PCR was performed with Light Cycler 480 SYBR Green I Kit (Roche Diagnostics GmbH, Manheim, Germany) using genetic-specific primers, as listed in Table 1. The amplification reactions were carried out on a Light Cycler 480 Instrument (Roche Diagnostics GmbH, Mannheim, Germany) with an initial hold step (95°C for 5 minutes) and 50 cycles of a three-step PCR (95°C for 15 seconds, 60°C for 15 seconds, 72°C for 30 seconds). The comparative CT-method [17] was used to determine the amount of target, normalized to an endogenous reference (18S) and relative to a calibrator (2-ΔΔCt) using the LightCycler 480 software (Roche, version 1.5.0).

Nuclear protein extraction

For nuclear protein extraction from the liver, 400 mg liver tissue was homogenized in 5 mL ice-cold buffer A [10 mM HEPES (pH 7.9), 150 mM NaCl, 0.6% NP-40, 0.1 mM EDTA, 1mM dithiothreitol (DTT), and 0.5 mM phenylmethylsulfonyl fluoride (PMSF)] on ice. The homogenate was centrifuged at 270×g for 30 s and the precipitate was discarded. The supernatant was kept on ice for 5 min and centrifuged again at 3,000×g for 20 min at 4°C. The supernatant was then mixed with 1 mL ice-cold buffer A and centrifuged again at 3,000×g for 5 min. The precipitate containing nuclei was reserved and homogenized in 100 μl Buffer B [20 mM HEPES (pH 7.9), 420 mM NaCl, 1.2 mM MgCl₂, 25% glycerol, 0.2 mM EDTA, 0.5 mM DDT, 0.5 mM PMSF, 1% protease inhibitor cocktail (P8340, Sigma)] for 60 min on ice. Nuclear lysate was centrifuged at
11,000× g for 10 min at 4°C. The supernatant was collected and protein concentrations were determined with the bicinchoninic acid (BCA) protein assay reagents (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. For nuclear protein extraction from cells, the cells were washed with ice-cold PBS/phosphatase inhibitors, collected with a cell scraper, and harvested by centrifugation. The cell pellet was then resuspended in hypotonic buffer and then kept on ice for 15 min. The suspension was then mixed with detergent and centrifuged for 30 s at 14,000 × g. The nuclear pellet obtained was resuspended in complete lysis buffer in the presence of the protease inhibitor cocktail, incubated for 30 min on ice, and centrifuged for 10 min at 14,000 × g. Protein concentrations were determined with the BCA protein assay reagents.

**Western blot**

Nuclear extracts were separated electrophoretically by SDS-PAGE and transferred to a polyvinylidene fluoride membrane. The membranes were incubated for 2 h with the following antibodies: SREBP-1, LXRα, PXR and PPARγ. Lamin A/C was used as a loading control for nuclear proteins. After washed in DPBS containing 0.05% Tween-20 four times for 10 min each, the membranes were incubated with goat anti-rabbit IgG antibody for 2 h. The membranes were then washed in DPBS containing 0.05% Tween-20 for four times for 10 min each again, followed by signal development using an ECL detection kit.

**Statistical analysis**

All data were expressed as means ± SEM. SPSS 13.0 statistical software was used for statistical analysis. All statistical tests were two-sided using an alpha level of 0.05. ANOVA and the Student-Newmann-Keuls post hoc test were used to determine differences among different groups. Student t test was used to determine differences between two groups.

**Results**

**Rifampicin induces hepatic lipid accumulation**

Although no significant difference on body weight was observed among different groups (data not shown), the absolute liver weight was significantly increased one week and
progressively elevated four weeks after rifampicin treatment (Fig 1A). Correspondingly, relative liver weight was slightly increased three days, significantly increased one week, and persistently elevated four weeks after rifampicin treatment (Fig 1B). The effects of rifampicin on biochemical parameters were analyzed. As expected, serum ALT level was significantly elevated in mice treated with rifampicin (Table 2). Moreover, the levels of serum TG and TG-VLDL were progressively reduced after a short elevation at 3 days after rifampicin treatment (Table 2). In addition, the levels of serum total cholesterol and Chol-HDL were progressively reduced in rifampicin-treated mice (Table 2). The effects of rifampicin on hepatic TG content were then analyzed. In contrast to reduction of serum TG, hepatic TG content was significantly elevated in rifampicin-treated mice (Fig 1C and 1D). An obvious hepatic lipid accumulation, as determined by Oil Red O staining, was observed in rifampicin-treated mice (Fig 1E).

**Fig 1. Rifampicin induces hepatic lipid accumulation.** All mice except controls were orally administered with rifampicin (200 mg/kg) daily for three days, one week or four weeks, respectively. Liver tissue was collected and weighed. (A) Absolute liver weight; (B) Relative liver weight. (C and D) Hepatic TG content was measured. (E) Hepatic lipid accumulation was evaluated using Oil Red staining. Upper row, representative photomicrograph of H&E staining; Lower row, representative photomicrograph of Oil Red staining. Original magnification, 100×. All data were expressed as means ± S.E.M. (n = 8). ** P < 0.01.
Table 2. Serum biochemical parameters.

| Parameters                      | Control            | 3d                | 1wk                | 4wk                |
|---------------------------------|--------------------|-------------------|--------------------|--------------------|
| Serum ALT(U/L)                  | 23.50±3.09         | 32.60±3.37**      | 44.98±6.36**       | 212.14±55.55**     |
| Serum TG (mmol/L)               | 1.97±0.13          | 2.82±0.26**       | 1.34±0.38**        | 0.89±0.20**        |
| Serum total cholesterol(mmol/L) | 4.40±0.49          | 3.86±0.40         | 2.86±0.21**        | 1.94±0.28**        |
| Serum Chol-HDL(mmol/L)          | 4.26±0.49          | 3.40±0.29         | 2.85±0.21*         | 1.95±0.26**        |
| Serum TG-VLDL(mmol/L)           | 0.73±0.05          | 1.04±0.12*        | 0.50±0.06**        | 0.33±0.03**        |

Data are means ± S.E.M.
* P < 0.05,
** P < 0.01 versus control group;
## P < 0.01 versus 3d group.

Rifampicin-mediated hepatic lipid accumulation associated with up-regulation of PPARγ

The effects of rifampicin on the expression of genes for fatty acid synthesis were analyzed. As shown in Fig 2A and 2B, mRNA levels of hepatic Fas and Acc were significantly increased when mice were administered with rifampicin. In addition, mRNA level of hepatic Scd-1 was rapidly elevated in rifampicin-treated mice (Fig 2C). SREBP-1c is one of the most important factors that regulate genes involved in hepatic fatty acid synthesis at the transcriptional level. The effects of rifampicin on hepatic nuclear SREBP-1c translocation were analyzed. As shown in Fig 2D, there was no significant difference on the level of hepatic nuclear SREBP-1c between rifampicin-treated mice and controls. LXR-α is another important transcriptional factor that regulates genes for fatty acids synthesis. The effects of rifampicin on hepatic nuclear LXR-α translocation were then analyzed. As shown in Fig 2E, rifampicin had little effect on hepatic nuclear LXR-α level.

Rifampicin up-regulates expression of genes for ω-oxidation of hepatic fatty acids

Carnitine palmitoyltransferase 1α (CPT-1α) is the key enzyme for β-oxidation of hepatic long-chain fatty acid. The effects of rifampicin on hepatic Cpt-1α expression were analyzed. As shown in Fig 3A, mRNA level of hepatic Cpt-1α was slightly elevated only in mice treated with rifampicin for four weeks. CYP4A10 and CYP4A14 are two key enzymes for ω-oxidation of hepatic fatty acids. The effects of rifampicin on the expression of hepatic Cyp4a10 and Cyp4a14 were then analyzed. Interestingly, hepatic Cyp4a10 mRNA was rapidly elevated when mice were administered with rifampicin (Fig 3B). In addition, hepatic Cyp4a14 mRNA was progressively up-regulated in rifampicin-treated mice (Fig 3C).

Rifampicin up-regulates expression of genes for transport of hepatic fatty acids

The effects of rifampicin on genes for transport of hepatic fatty acids were evaluated. As shown in Fig 4A, mRNA level of hepatic Cd36 was progressively elevated after mice were administered with rifampicin. Moreover, hepatic fatty acid transport protein (Fatp) and low-density lipoprotein receptor (Ldlr) were slightly up-regulated in rifampicin-treated mice (Fig 4B and 4F). As shown in Fig 4C–4E, rifampicin had little effect on the expression of hepatic L-fabp, Mttp and Apob.
Rifampicin up-regulates hepatic PPARγ expression

Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcriptional factor. The effects of rifampicin on hepatic PPARγ expression were analyzed. As shown in Fig 5A, hepatic Pparγ mRNA was progressively up-regulated when mice were administered with rifampicin. Moreover, the level of hepatic PPARγ protein was markedly elevated in rifampicin-treated mice (Fig 5B). In addition, the level of hepatic nuclear PPARγ was progressively increased in rifampicin-treated mice (Fig 5C).
PLOS ONE | DOI:10.1371/journal.pone.0165787 November 2, 2016 8 / 14

Rifampicin activates hepatic PXR signaling

PXR, which is highly expressed in liver, plays an important role in drug metabolism. The effects of rifampicin on hepatic PXR signaling were analyzed. As shown in Fig 6A, the level of hepatic nuclear PXR was progressively increased when mice were administered with rifampicin. In parallel, mRNA level of hepatic Cyp3a11, a downstream target gene of PXR, was up-regulated in rifampicin-treated mice (Fig 6B).

Discussion

Our previous study demonstrated that rifampicin, one of the most commonly used anti-tubercular drugs, caused intrahepatic cholestasis [15]. The present study investigated the effects of rifampicin on hepatic lipid metabolism in mice. Our results showed that serum TG and total cholesterol levels were progressively reduced when mice were administered with rifampicin for more than one week. By contrast, hepatic TG content was significantly elevated in rifampicin-treated mice. Moreover, an obvious hepatic lipid accumulation, as determined by Oil Red O staining, was observed when mice were administered with rifampicin for more than one week. These results suggest that rifampicin not only impairs bile transport but also hepatic lipid metabolism.

Increasing evidence demonstrates that hepatic de novo lipogenesis contributes much to the development of steatosis [18]. The present study investigated the effects of rifampicin on several key genes for hepatic fatty acid synthesis. As expected, mRNA levels of hepatic Acc and Fas were significantly elevated when mice were administered with rifampicin for three days. In addition, hepatic Scd-1 was rapidly up-regulated by rifampicin. These results are in agreement with an in vitro report, in which SCD-1 and long chain free fatty acid elongase were up-regulated in rifampicin-treated HepG2 cells [19]. These results suggest that rifampicin-induced hepatic lipid accumulation is partially attributed to the increased hepatic lipid synthesis.

SREBP-1c is the most important transcription factor that regulates genes for hepatic fatty acid and TG synthesis [20, 21]. The present study investigated whether rifampicin activates SREBP-1c in mouse liver. Our results showed that there was no significant difference on hepatic nuclear SREBP-1c level between rifampicin-treated mice and controls. LXR-α is a nuclear receptor that not only transcriptionally regulates hepatic SREBP-1c and its target genes but also
directly modulates genes for hepatic fatty acid synthesis [22–24]. The present study found that no significant difference on hepatic nuclear LXR-α level was observed between rifampicin-treated mice and controls. These results suggest that rifampicin up-regulates key genes for hepatic fatty acid synthesis and elevates hepatic lipid synthesis independent of SREBP-1c and LXR-α activation. PXR is well known as a nuclear receptor that regulates xenobiotic and drug metabolism and elimination [25]. According to an in vitro report, xenobiotic or drug-activated PXR up-regulates FAS expression and promotes de novo lipogenesis via activation of the non-classical S14 pathway in human hepatocytes [26]. Indeed, the present study showed that hepatic PXR was rapidly activated in rifampicin-treated mice. Therefore, it is reasonable to assume that rifampicin-activated PXR is involved in up-regulation of genes for fatty acid synthesis.

In addition to hepatic de novo lipogenesis, the increased uptake of free fatty acids from circulation to liver plays an important role in the development of hepatic lipid accumulation [27].

![Graphs showing gene expression](image-url)

**Fig 4. Rifampicin up-regulates expression of genes for transport of hepatic fatty acids.** All mice except controls were orally administered with rifampicin (200 mg/kg) daily for three days, one week or four weeks, respectively. Liver tissue was collected. Hepatic Cd36, Fatp, L-fabp, Mttp, Apob and Ldlr were measured using real-time RT-PCR. (A) Cd36; (B) Fatp; (C) L-fabp; (D) Mttp; (E) Apob; (F) Ldlr. All data were expressed as means ± S.E.M. (n = 8). * P < 0.05, ** P < 0.01.

doi:10.1371/journal.pone.0165787.g004
The class B scavenger receptor CD36 is a membrane receptor that participates in the uptake of fatty acids from circulation to hepatocyte [28, 29]. Several studies demonstrate that an increased hepatic CD36 expression is associated with enhanced susceptibility to nonalcoholic fatty liver disease [30–32]. The present study investigated the effects of rifampicin on genes for

![Fig 5. Rifampicin up-regulates hepatic PPARγ expression.](image)

All mice except controls were orally administered with rifampicin (200 mg/kg) daily for three days, one week or four weeks, respectively. Liver tissue was collected. (A) Hepatic Ppar mRNA was measured using real-time RT-PCR. (B) Hepatic PPARγ was measured using Western blot. PPARγ was normalized to the level of β-actin in the same sample. (C) Nuclear PPARγ was measured using Western blot. PPARγ was normalized to the level of Lamin A/C in the same sample. All data were expressed as means ± S.E.M. (n = 8). * P < 0.05, ** P < 0.01.

doi:10.1371/journal.pone.0165787.g005

Fig 6. Rifampicin activates hepatic PXR signaling. All mice except controls were orally administered with rifampicin (200 mg/kg) daily for three days, one week or four weeks, respectively. Liver tissue was collected. (A) Nuclear PXR was measured using Western blot. PXR was normalized to the level of Lamin A/C in the same sample. (B) Hepatic Cyp3a11 mRNA was measured using real-time RT-PCR. All data were expressed as means ± S.E.M. (n = 8). * P < 0.05, ** P < 0.01.

doi:10.1371/journal.pone.0165787.g006
transport of hepatic fatty acids. We showed that hepatic \textit{Cd36} expression was progressively up-regulated after mice were administered with rifampicin. In addition, mRNA levels of hepatic \textit{Fatp}, a fatty acid transporter that participates in the uptake of long-chain fatty acids [33], and \textit{Ldlr}, a surface receptor that removes cholesterol-carrying LDL from plasma by receptor-mediated endocytosis [34], were slightly increased in rifampicin-treated mice. These results indicate that rifampicin-evoked hepatic lipid accumulation is, at least partially, due to the increased uptake of free fatty acids from circulation to liver.

\textit{PPAR}_{\gamma} is a ligand-activated transcriptional factor that is predominantly expressed in adipose tissues and to a lesser extent in liver [35, 36]. Several studies found that hepatic \textit{PPAR}_{\gamma} was up-regulated in high-fat diet-fed rodent animals [36, 37]. According to a recent report, \textit{PPAR}_{\gamma} promotes hepatic lipid uptake and lipid droplet accumulation [38]. Indeed, the class B scavenger receptor CD36 is a downstream target gene of \textit{PPAR}_{\gamma} [39]. The present study investigated whether hepatic \textit{PPAR}_{\gamma} was activated by rifampicin. Consistent with hepatic \textit{Cd36} up-regulation, nuclear \textit{PPAR}_{\gamma} level was progressively elevated in rifampicin-treated mice. The mechanism by which rifampicin activates hepatic \textit{PPAR}_{\gamma} remains obscure. The present study showed that hepatic \textit{Ppar}_{\gamma} mRNA was up-regulated by more than ten folds when mice were treated with rifampicin for four weeks. Correspondingly, the level of hepatic \textit{PPAR}_{\gamma} protein was elevated by more than ten folds in rifampicin-treated mice. These results suggest that rifampicin up-regulates hepatic \textit{PPAR}_{\gamma} expression at a transcriptional level. According to an earlier study, \textit{PPAR}_{\gamma} is a downstream target of PXR in mouse liver [40]. The present study showed that the level of nuclear PXR was significantly increased by more than ten folds when mice were treated with rifampicin for four weeks. Moreover, mRNA level of \textit{Cyp3a11}, a downstream target gene of PXR, was significantly up-regulated in rifampicin-treated mice. Taken together, these results suggest that the increased uptake of fatty acids from circulation into liver might be partially attributed to rifampicin-induced PXR activation and \textit{PPAR}_{\gamma} up-regulation in mouse liver.

\textit{CPT-1\alpha} is the key enzyme for $\beta$-oxidation of hepatic long-chain fatty acid [41]. On the other hand, \textit{CYP4A10} and \textit{CYP4A14} are two key enzymes for $\omega$-oxidation of hepatic fatty acids [42]. Increasing evidence demonstrates that decreased hepatic fatty acids oxidation partially contributed to the development of NAFLD [43, 44]. The present study analyzed the effects of rifampicin on hepatic $\beta$-oxidation and $\omega$-oxidation of hepatic fatty acids in mice. Unexpectedly, hepatic \textit{Cpt-1\alpha} expression was slightly elevated after mice were administered with rifampicin for four weeks. Moreover, the level of hepatic \textit{Cyp4a10} mRNA was rapidly increased in rifampicin-treated mice. In addition, hepatic \textit{Cyp4a14} was progressively up-regulated by rifampicin. These results suggest that rifampicin-induced hepatic lipid accumulation is independent of the decreased hepatic fatty acid oxidation.

In summary, the present study investigated the effects of rifampicin on hepatic lipid metabolism. Our results showed that rifampicin significantly elevated hepatic TG content and caused hepatic lipid accumulation in mice. We found that rifampicin rapidly elevated expression of genes for de novo lipogenesis and progressively up-regulated genes for uptake of fatty acids in mouse liver. Our results suggest that the increased hepatic lipid synthesis and uptake of fatty acids from circulation into liver jointly contribute to rifampicin-induced hepatic lipid accumulation. The increased uptake of fatty acids from circulation into liver might be partially attributed to rifampicin-induced up-regulation of \textit{PPAR}_{\gamma} and its target genes.

**Author Contributions**

**Conceptualization:** XC DXX.

**Data curation:** CZ.
Formal analysis: JHH.

Funding acquisition: CZ XC DXX.

Investigation: CZ XC DXX.

Methodology: JHH CZ DGZ LL.

Project administration: XC DXX.

Resources: DXX.

Software: CZ.

Supervision: CZ XC DXX.

Validation: CZ.

Visualization: JHH DXX.

Writing – original draft: XC DXX.

Writing – review & editing: DXX.

References
1. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepato-

tol. 2013; 10: 656–665. doi: 10.1038/nrgastro.2013.183 PMID: 24080776
2. Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of Nonalcoholic Fatty Liver Disease and Economy. Dig Dis Sci. 2015; 60: 3194–3202. doi: 10.1007/s10620-015-3728-3 PMID: 26017679
3. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010; 51: 679–689. doi: 10.1002/hep.23280 PMID: 20041406
4. Anstee OM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10: 330–344. doi: 10.1038/nrgastro.2013.41 PMID: 23507799
5. Asrih M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: the good and the bad. Clin Nutr.
2014; 33: 186–190. doi: 10.1016/j.clnu.2013.11.003 PMID: 24262589
6. Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis. 2014; 34: 205–214. doi:
10.1055/s-0034-1375960 PMID: 24879984
7. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006; 11: 699–707. doi:
10.1111/j.1440-1843.2006.00941.x PMID: 17052297
8. Testmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antitubercul-
osis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008; 23: 192–
202. doi: 10.1111/j.1440-1746.2007.05207.x PMID: 17995946
9. Meng Q, Zhang G, Shen C, Qiu H. Sensitivities of gel entrapped hepatocytes in hollow fibers to hepato-
toxic drug. Toxicol Lett. 2006; 166: 19–26. doi: 10.1016/j.toxlet.2006.05.006 PMID: 16814964
10. Shen C, Cheng X, Li D, Meng Q. Investigation of rifampicin-induced hepatotoxicity in rat hepatocytes
maintained in gel entrapment culture. Cell Biol Toxicol. 2009; 25: 265–274. doi: 10.1007/s10565-008-
9076-8 PMID: 18496758
11. Shih TY, Ho SC, Hsiong CH, Huang TY, Hu OY. Selected pharmaceutical excipient prevent isoniazid
and rifampicin induced hepatotoxicity. Curr Drug Metab. 2013; 14: 720–728. PMID: 23701163
12. Enriquez-Cortina C, Almonte-Becerril M, Clavijo-Cornejo D, Palestino-Dominguez M, Bello-Monroy O,
Nurco N, et al. Hepatocyte growth factor protects against isoniazid/rifampicin-induced oxidative liver
damage. Toxicol Sci. 2013; 135: 26–36. doi: 10.1093/toxsci/kft134 PMID: 23764483
13. Chen X, Xu J, Zhang C, Yu T, Wang H, Zhao M, et al. The protective effects of ursodeoxycholic acid on
isoniazid plus rifampicin induced liver injury in mice. Eur J Pharmacol. 2011; 659: 53–60. doi: 10.1016/
 j.ejphar.2011.03.007 PMID: 21419764
14. Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhal GK, et al. Mitochondrial oxidative
damage and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol.
2006; 45: 117–126. doi: 10.1016/j.jhep.2006.01.027 PMID: 16545483
Zhou J, Zhai YG, Mu Y, Gong HB, Hirdesh U, David T, et al. A novel pregnane X receptor-mediated... 

Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3:1101–1108. PMID: 18546601

Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008; 118: 829–838. doi: 10.1172/JCI34275 PMID: 18317565

Zhang J, Wei Y, Hu B, Huang M, Xie W, Zhai Y, et al. Activation of Human Stearoyl-Coenzyme A Desaturase 1 Contributes to the Lipogenic Effect of PXR in HepG2 Cells. PLoS One. 2013; 8: e67959. doi: 10.1371/journal.pone.0067959 PMID: 23874477

Jeon TI, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab. 2013; 23: 65–72.

Xu X, So JS, Park JG, Lee AH. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis. 2013; 33: 301–311. doi: 10.1055/s-0033-1358523 PMID: 24222088

Repä JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000; 14: 2819–2830. PMID: 11090130

Schulz JR, Tu H, Lukan A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000; 14: 2831–2838. PMID: 11090131

Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem. 2002; 277: 11019–11025. doi: 10.1074/jbc.M111041200 PMID: 11790787

Staudinger JL, Woody S, Sun M, Cui W. Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver. Drug Metab Rev. 2013; 45: 48–59. doi: 10.3109/03602532.2012.748793 PMID: 23330541

Moreau A, Ténel C, Beylot M, Albalea V, Tamasi V, Umbdenstock T, et al. A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology. 2009; 49: 2068–2079. doi: 10.1002/hep.22907 PMID: 19437491

Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013; 48: 434–441. doi: 10.1007/s00535-013-0758-5 PMID: 23397118

He J, Lee JH, Feabraio M, Xie W. The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp Biol Med. 2011; 236: 1116–1121.

Silverstein RL, Feabraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009; 2: re3. doi: 10.1126/scisignal.272re3 PMID: 19471024

Sheedfar F, Sung MM, Aparicio-Vergara M, Kloosterhuis NJ, Miquillena-Colina ME, Vargas-Castrillo J, et al. Increased hepatic CD36 expression with age is associated with enhanced susceptibility to non-alcoholic fatty liver disease. Aging. 2014; 6: 281–295. doi: 10.18632/aging.100652 PMID: 24751397

Miquillena-Colina ME, Lima-Cabello E, Sánchez-Campos S, García-Mediavilla MV, Fernández-Bermejo M, Lozano-Rodríguez T, et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 2011; 60: 1394–1402. doi: 10.1136/gut.2010.222844 PMID: 21270117

García-Monzón C, Lo Iacono O, Crespo J, Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M, et al. Increased soluble CD36 is linked to advanced steatosis in non-alcoholic fatty liver disease. Eur J Clin Invest. 2014; 44: 65–73. doi: 10.1111/eci.12192 PMID: 24134687

Kazantzis M, Stahl A. Fatty acid transport proteins, implications in physiology and disease. Biochim Biophys Acta. 2012; 1821: 852–857. doi: 10.1016/j.bbalip.2011.09.010 PMID: 21979150

Pieper-Furst U, Lammert F. Low-density lipoprotein receptors in liver: old acquaintances and a newcomer. Biochim Biophys Acta. 2013; 1831: 1191–1198. PMID: 24046859

Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 1994; 135: 798–800. doi: 10.1210/endo.135.2.8033830 PMID: 8033830

Vidal-Puig A, Jimenez-Llñan M, Howell BB, Hamann A, Hu E, Spiegelman B, et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest. 1996; 97: 2553–2561. doi: 10.1172/JCI118703 PMID: 8647948
37. Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, Miyoshi S, et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun. 2005; 336: 215–222. doi: 10.1016/j.bbrc.2005.08.070 PMID: 16125673

38. Morán-Salvador E, López-Parra M, García-Alonso V, Titos E, Martínez-Clemente M, González-Pérez A, et al. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J. 2011; 25: 2538–2550. doi: 10.1096/fj.10-173716 PMID: 21507897

39. Zhou J, Febbraio Maria, Wada Taira, Zhai YG, Kuruba Ramalinga, He JH, et al. Hepatic fatty acid transporter Cld6 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology. 2008; 134: 556–567. doi: 10.1053/gastro.2007.11.037 PMID: 18242221

40. Zhou J, Zhai Y, Mu Y, Gong H, Uppal H, Toma D, et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J Biol Chem. 2006; 281: 15013–15020. doi: 10.1074/jbc.M511116200 PMID: 16556603

41. Schreurs M, Kuipers F, van der Leij FR. Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes Rev. 2010; 11: 380–388. doi: 10.1111/j.1467-789X.2009.00642.x PMID: 19694967

42. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000; 105: 1067–1075. doi: 10.1172/JCI8814 PMID: 10772651

43. Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci. 2014; 15: 8713–8742. doi: 10.3390/ijms15058713 PMID: 24837835

44. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013; 58: 1497–1507. doi: 10.1002/hep.26226 PMID: 23299992